The Impact of Polypharmacy on Management of Lower Urinary Tract Symptoms in Parkinson's Disease.
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
accepted:
31
07
2023
medline:
21
9
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
ppublish
Résumé
Lower urinary tract (LUT) symptoms are a common presentation of autonomic dysfunction in Parkinson's disease (PD). Symptoms significantly impact quality of life and are associated with worsening of motor symptoms and increased risk for falls. Different medical co-morbidities can often contribute to LUT symptoms, and a thorough evaluation therefore becomes essential. The effects of medications used for Parkinson's disease and other co-existing medical co-morbidities on LUT symptoms is often underestimated. Treatment options include behavioural therapy, oral agents such as antimuscarinic and beta-3 receptor agonist agents, botulinum toxin and neuromodulation. The first-line oral agents cause adverse effects that may exacerbate pre-existing Parkinson's disease-related symptoms. Furthermore, these oral agents can interact with other medications used in Parkinson's disease, and the challenges posed by interactions on pharmacological effects and metabolism are discussed. Knowledge about drug interactions can help in effective management of such patients and mitigate the risks for developing adverse effects.
Identifiants
pubmed: 37651023
doi: 10.1007/s40266-023-01060-2
pii: 10.1007/s40266-023-01060-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
909-917Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Ragab MM, Mohammed ES. Idiopathic Parkinson’s disease patients at the urologic clinic. Neurourol Urodyn. 2011;30(7):1258–61.
pubmed: 21404318
doi: 10.1002/nau.20983
Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci. 2001;92(1–2):76–85.
pubmed: 11570707
doi: 10.1016/S1566-0702(01)00295-8
Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord. 2010;25(15):2493–500.
pubmed: 20922807
doi: 10.1002/mds.23394
Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–9.
pubmed: 19514014
doi: 10.1002/mds.22643
Andersen JT. Disturbances of bladder and urethral function in Parkinson’s disease. Int Urol Nephrol. 1985;17(1):35–41.
pubmed: 3997405
doi: 10.1007/BF02089401
Berger Y, Blaivas JG, DeLaRocha ER, Salinas JM. Urodynamic findings in Parkinson’s disease. J Urol. 1987;138(4):836–8.
pubmed: 3656541
doi: 10.1016/S0022-5347(17)43390-8
Rosello A, Pouwels KB, Domenech DECM, Vank E, Hayward AC, Hopkins S, et al. Seasonality of urinary tract infections in the United Kingdom in different age groups: longitudinal analysis of The Health Improvement Network (THIN). Epidemiol Infect. 2018;146(1):37–45.
pubmed: 29168442
doi: 10.1017/S095026881700259X
Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N. Falls in outpatients with Parkinson’s disease: frequency, impact and identifying factors. J Neurol. 2005;252(11):1310–5.
pubmed: 15895303
doi: 10.1007/s00415-005-0855-3
Temml C, Ponholzer A, Gutjahr G, Berger I, Marszalek M, Madersbacher S. Nocturia is an age-independent risk factor for hip-fractures in men. Neurourol Urodyn. 2009;28(8):949–52.
pubmed: 19301408
doi: 10.1002/nau.20712
McGrother CW, Jagger C, Clarke M, Castleden CM. Handicaps associated with incontinence: implications for management. J Epidemiol Community Health. 1990;44(3):246–8.
pubmed: 2148771
pmcid: 1060651
doi: 10.1136/jech.44.3.246
Yeo L, Singh R, Gundeti M, Barua JM, Masood J. Urinary tract dysfunction in Parkinson’s disease: a review. Int Urol Nephrol. 2012;44(2):415–24.
pubmed: 21553114
doi: 10.1007/s11255-011-9969-y
Xu D, Han S, Wang J, Feng J. Relationship between lower urinary tract dysfunction and clinical features in Chinese Parkinson’s disease patients. Parkinsons Dis. 2019;2019:6820937.
pubmed: 30949327
pmcid: 6425341
Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson’s disease. Eur J Neurol. 2005;12(11):842–50.
pubmed: 16241972
doi: 10.1111/j.1468-1331.2005.01087.x
Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson’s disease. Neurobiol Dis. 2012;46(3):565–71.
pubmed: 22015601
doi: 10.1016/j.nbd.2011.10.002
Batla A, Tayim N, Pakzad M, Panicker JN. Treatment options for urogenital dysfunction in Parkinson’s disease. Curr Treat Options Neurol. 2016;18(10):45.
pubmed: 27679448
pmcid: 5039223
doi: 10.1007/s11940-016-0427-0
Ogawa T, Sakakibara R, Kuno S, Ishizuka O, Kitta T, Yoshimura N. Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy. Nat Rev Urol. 2017;14(2):79–89.
pubmed: 27958390
doi: 10.1038/nrurol.2016.254
Yamamoto T, Asahina M, Yamanaka Y, Uchiyama T, Hirano S, Fuse M, et al. The utility of post-void residual volume versus sphincter electromyography to distinguish between multiple system atrophy and Parkinson’s disease. PLoS ONE. 2017;12(1): e0169405.
pubmed: 28060892
pmcid: 5217958
doi: 10.1371/journal.pone.0169405
Tateno F, Sakakibara R, Ogata T, Kishi M, Tsuyusaki Y, Takahashi O, et al. Lower urinary tract function in dementia with Lewy bodies (DLB). Mov Disord. 2015;30(3):411–5.
pubmed: 25356960
doi: 10.1002/mds.25985
Ransmayr GN, Holliger S, Schletterer K, Heidler H, Deibl M, Poewe W, et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology. 2008;70(4):299–303.
pubmed: 18209204
doi: 10.1212/01.wnl.0000296826.61499.26
Stewart RB, Moore MT, May FE, Marks RG, Hale WE. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc. 1992;40(12):1217–20.
pubmed: 1447437
doi: 10.1111/j.1532-5415.1992.tb03645.x
Nakagawa H, Niu K, Hozawa A, Ikeda Y, Kaiho Y, Ohmori-Matsuda K, et al. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J Urol. 2010;184(4):1413–8.
pubmed: 20727545
doi: 10.1016/j.juro.2010.05.093
Parsons JK, Mougey J, Lambert L, Wilt TJ, Fink HA, Garzotto M, et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int. 2009;104(1):63–8.
pubmed: 19154508
pmcid: 3031126
doi: 10.1111/j.1464-410X.2008.08317.x
Weiss JP. Nocturia: focus on etiology and consequences. Rev Urol. 2012;14(3–4):48–55.
pubmed: 23526404
pmcid: 3602727
Batla A, Simeoni S, Uchiyama T, deMin L, Baldwin J, Melbourne C, et al. Exploratory pilot study of exogenous sustained-release melatonin on nocturia in Parkinson’s disease. Eur J Neurol. 2021;28(6):1884–92.
pubmed: 33576095
doi: 10.1111/ene.14774
Batla A, Phe V, De Min L, Panicker JN. Nocturia in Parkinson’s disease: why does it occur and how to manage? Mov Disord Clin Pract. 2016;3(5):443–51.
pubmed: 30363512
pmcid: 6178648
doi: 10.1002/mdc3.12374
Sakakibara R, Shimizu A, Takahashi O, Ogata T, Sawai S, Uchiyama T, et al. Parkinson’s disease and nocturnal polyuria. Neurol Clin Neurosci. 2023;11(1):27–31.
doi: 10.1111/ncn3.12686
Li FF, Cui YS, Yan R, Cao SS, Feng T. Prevalence of lower urinary tract symptoms, urinary incontinence and retention in Parkinson’s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2022;14: 977572.
pubmed: 36172485
pmcid: 9510898
doi: 10.3389/fnagi.2022.977572
Sammour ZM, Gomes CM, Barbosa ER, Lopes RI, Sallem FS, Trigo-Rocha FE, et al. Voiding dysfunction in patients with Parkinson’s disease: impact of neurological impairment and clinical parameters. Neurourol Urodyn. 2009;28(6):510–5.
pubmed: 19191278
doi: 10.1002/nau.20681
Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and Parkinson’s disease—should transurethral resection of the prostate be avoided? J Urol. 2009;181(5):2209–13.
pubmed: 19296974
doi: 10.1016/j.juro.2009.01.049
Iacovelli E, Gilio F, Meco G, Fattapposta F, Vanacore N, Brusa L, et al. Bladder symptoms assessed with overactive bladder questionnaire in Parkinson’s disease. Mov Disord. 2010;25(9):1203–9.
pubmed: 20310046
doi: 10.1002/mds.23093
Godmer M, Guinet-Lacoste A, Charvier K, Luauté J, Rode G, Soler JM, et al. Existe-t-il une obstruction autre que prostatique dans la maladie de Parkinson idiopathique? Prog Urol. 2019;29(11):579–85.
pubmed: 31302008
doi: 10.1016/j.purol.2019.06.001
McDonald C, Rees J, Winge K, Newton JL, Burn DJ. Bladder training for urinary tract symptoms in Parkinson disease: a randomized controlled trial. Neurology. 2020;94(13):e1427–33.
pubmed: 32054791
pmcid: 7274915
doi: 10.1212/WNL.0000000000008931
Vaughan CP, Burgio KL, Goode PS, Juncos JL, McGwin G, Muirhead L, et al. Behavioral therapy for urinary symptoms in Parkinson’s disease: a randomized clinical trial. Neurourol Urodyn. 2019;38(6):1737–44.
pubmed: 31187552
pmcid: 6660386
doi: 10.1002/nau.24052
Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, Parkinson’s Disease Subcomittee TNPCiTICS. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn. 2016;35(5):551–63.
pubmed: 25810035
doi: 10.1002/nau.22764
Brusa L, Petta F, Pisani A, Moschella V, Iani C, Stanzione P, et al. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology. 2007;68(18):1455–9.
pubmed: 17470746
doi: 10.1212/01.wnl.0000260605.12506.86
Brusa L, Ponzo V, Stefani A, Ceravolo R, Palermo G, Agro EF, et al. Extended release levodopa at bedtime as a treatment for nocturiain Parkinson’s disease: an open label study. J Neurol Sci. 2020;410: 116625.
pubmed: 31877419
doi: 10.1016/j.jns.2019.116625
Gomez-Lopez A, Sanchez-Sanchez A, Natera-Villalba E, Ros-Castello V, Beltran-Corbellini A, Fanjul-Arbos S, et al. SURINPARK: safinamide for urinary symptoms in Parkinson's Disease. Brain Sci. 2021;11(1):57.
Tateno H, Uchiyama T, Yamamoto T, Watanabe Y, Hashimoto K, Shibata-Yamaguchi C, et al. Amantadine can ameliorate lower urinary tract dysfunction and nocturnal polyuria in patients with Parkinson disease and vascular parkinsonism. Dokkyo J Med Sci. 2015;42(1):21–9.
Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(5):514–20.
pubmed: 25814050
doi: 10.1016/j.parkreldis.2015.02.025
Palleschi G, Pastore AL, Stocchi F, Bova G, Inghilleri M, Sigala S, et al. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment. Clin Neuropharmacol. 2006;29(4):220–9.
pubmed: 16855424
doi: 10.1097/01.WNF.0000228177.75711.0f
Bennett N, O’Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol. 2004;171(2 Pt 1):749–51.
pubmed: 14713802
doi: 10.1097/01.ju.0000103274.38694.b1
Macdiarmid SA. Concomitant medications and possible side effects of antimuscarinic agents. Rev Urol. 2008;10(2):92–8.
pubmed: 18660862
pmcid: 2483325
Barrett MJ, Sargent L, Nawaz H, Weintraub D, Price ET, Willis AW. Antimuscarinic anticholinergic medications in Parkinson disease: to prescribe or deprescribe? Mov Disord Clin Pract. 2021;8(8):1181–8.
pubmed: 34765683
pmcid: 8564829
doi: 10.1002/mdc3.13347
Bharucha AE, Isowa H, Hiro S, Guan Z. Differential effects of selective and non-selective muscarinic antagonists on gastrointestinal transit and bowel function in healthy women. Neurogastroenterol Motil. 2013;25(1):e35–43.
pubmed: 23171069
doi: 10.1111/nmo.12043
Provitera V, Nolano M, Caporaso G, Stancanelli A, Mozzillo S, Piscosquito G, et al. Asymmetric sudomotor impairment in Parkinson disease. Clin Neurophysiol. 2019;130(1): e11.
doi: 10.1016/j.clinph.2018.09.073
Ahmad S, Reyes JVM, Lieber J. Oxybutynin-induced hyperthermia in a patient with Parkinson’s disease. Cureus. 2021;13(4): e14701.
pubmed: 34055543
pmcid: 8153843
Madan A, Brown T, Ray S, Agarwal P, Roy-Faderman I, Burdick D. A novel trial of mirabegron and behavioral modification including pelvic floor exercise for overactive bladder in Parkinson’s disease (MAESTRO). Cureus. 2022;14(11): e31818.
pubmed: 36425049
pmcid: 9682970
Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Efficacy, safety, and tolerability of mirabegron in patients aged >/=65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol. 2020;77(2):211–20.
pubmed: 31733990
doi: 10.1016/j.eururo.2019.10.002
Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord. 1995;10(3):337–40.
pubmed: 7651453
doi: 10.1002/mds.870100318
Fralick M, Schneeweiss S, Wallis CJD, Jung EH, Kesselheim AS. Desmopressin and the risk of hyponatremia: a population-based cohort study. PLoS Med. 2019;16(10): e1002930.
pubmed: 31634354
pmcid: 6802819
doi: 10.1371/journal.pmed.1002930
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review. Mov Disord. 2019;34(2):180–98.
pubmed: 30653247
pmcid: 6916382
doi: 10.1002/mds.27602
Hu J-C, Hsu L-N, Lee W-C, Chuang Y-C, Wang H-J. Role of urological botulinum toxin-a injection for overactive bladder and voiding dysfunction in patients with Parkinson’s disease or post-stroke. Toxins (Basel). 2023;15(2):166.
pubmed: 36828479
pmcid: 9965145
doi: 10.3390/toxins15020166
Atamian A, Sichez PC, Michel F, Bandelier Q, Fall M, Gaillet S, et al. Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson’s disease. Prog Urol. 2021;31(7):430–8.
pubmed: 33579624
doi: 10.1016/j.purol.2021.01.004
Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011;186(3):960–4.
pubmed: 21791351
doi: 10.1016/j.juro.2011.04.071
Knüpfer SC, Schneider SA, Averhoff MM, Naumann CM, Deuschl G, Jünemann K-P, et al. Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson’s disease. BMC Urol. 2016;16(1):55.
pubmed: 27596481
pmcid: 5011793
doi: 10.1186/s12894-016-0174-2
Anderson RU, Orenberg EK, Glowe P. OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson’s disease. Urology. 2014;83(1):22–7.
pubmed: 24231202
doi: 10.1016/j.urology.2013.09.017
Vurture G, Peyronnet B, Feigin A, Biagioni MC, Gilbert R, Rosenblum N, et al. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson’s disease. Neurourol Urodyn. 2018;37(8):2669–77.
pubmed: 29767449
doi: 10.1002/nau.23717
Kabay S, Kabay SC. The sustained therapeutic effects of percutaneous posterior tibial nerve stimulation in the treatment of neurogenic lower urinary tract symptoms in patients with Parkinson’s disease: 24-months clinical and urodynamic results. Urology. 2021;153:49–55.
pubmed: 33561470
doi: 10.1016/j.urology.2021.01.044
Araujo TG, Schmidt AP, Sanches PRS, Silva Junior DP, Rieder CRM, Ramos JGL. Transcutaneous tibial nerve home stimulation for overactive bladder in women with Parkinson’s disease: a randomized clinical trial. Neurourol Urodyn. 2021;40(1):538–48.
pubmed: 33326648
doi: 10.1002/nau.24595
Perissinotto MC, D’Ancona CA, Lucio A, Campos RM, Abreu A. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. J Wound Ostomy Cont Nurs. 2015;42(1):94–9.
doi: 10.1097/WON.0000000000000078
McClurg D, Elders A, Hagen S, Mason H, Booth J, Cunnington AL, et al. Stimulation of the tibial nerve—a randomised trial for urinary problems associated with Parkinson's—the STARTUP trial. Age Ageing. 2022;51(6):afac114.
Martin S, Zillioux J, Goldman HB. Is sacral neuromodulation effective in patients with Parkinson’s disease? A retrospective review. Neurourol Urodyn. 2022;41(4):955–61.
pubmed: 35238421
doi: 10.1002/nau.24900
Macleod AD, Goddard H, Counsell CE. Co-morbidity burden in Parkinson’s disease: comparison with controls and its influence on prognosis. Parkinsonism Relat Disord. 2016;28:124–9.
pubmed: 27210815
pmcid: 4925465
doi: 10.1016/j.parkreldis.2016.05.013
McLean G, Hindle JV, Guthrie B, Mercer SW. Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database. BMC Neurol. 2017;17(1):126.
pubmed: 28666413
pmcid: 5493890
doi: 10.1186/s12883-017-0904-4
Minar M, Dragasek J, Valkovic P, Valkovic P. Psychiatric and somatic co-morbidities in patients with Parkinson’s disease: a STROBE-compliant national multi-center, cross-sectional, observational study COSMOS in Slovakia. Neuro Endocrinol Lett. 2022;43(1):39–44.
pubmed: 35490424
Bhagavathula AS, Tesfaye W, Vidyasagar K, Fialova D. Polypharmacy and Hyperpolypharmacy in older individuals with Parkinson's disease: a systematic review and meta-analysis. Gerontology. 2022;68(10):1081–90.
Srikrishna S, Robinson D, Cardozo L. Important drug–drug interactions for treatments that target overactive bladder syndrome. Int Urogynecol J. 2014;25(6):715–20.
pubmed: 24232071
doi: 10.1007/s00192-013-2259-8
Vouri SM, Schootman M, Strope SA, Xian H, Olsen MA. Antimuscarinic use and discontinuation in an older adult population. Arch Gerontol Geriatr. 2019;80:1–11.
pubmed: 30268971
doi: 10.1016/j.archger.2018.09.005
Leone Roberti Maggiore U, Salvatore S, Alessandri F, Remorgida V, Origoni M, Candiani M, et al. Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. Expert Opin Drug Metab Toxicol. 2012;8(11):1387–408.
pubmed: 22871042
doi: 10.1517/17425255.2012.714365
Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, et al. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet. 2014;39(1):43–52.
pubmed: 23728524
doi: 10.1007/s13318-013-0133-1
De Vreese LP, Mantesso U, De Bastiani E, Marangoni A, Weger E, Gomiero T. Anticholinergic burden in adult and elderly people with intellectual disabilities: results from an Italian multicenter cross-sectional study. PLoS ONE. 2018;13(10): e0205897.
pubmed: 30379948
pmcid: 6209221
doi: 10.1371/journal.pone.0205897
Boustani M, Campbell N, Munger S, Maidment I, Fox C. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311–20.
doi: 10.2217/1745509X.4.3.311
Welsh TJ, van der Wardt V, Ojo G, Gordon AL, Gladman JRF. Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: a systematic review of reviews. Drugs Aging. 2018;35(6):523–38.
pubmed: 29736815
doi: 10.1007/s40266-018-0549-z
De Germay S, Montastruc J-L, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, et al. Atropinic (anticholinergic) burden in Parkinson’s disease. Mov Disord. 2016;31(5):632–6.
pubmed: 27028036
doi: 10.1002/mds.26595
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.
pubmed: 25621434
pmcid: 4358759
doi: 10.1001/jamainternmed.2014.7663
Welk B, McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020;126(1):183–90.
pubmed: 32167223
doi: 10.1111/bju.15040
Kay GG, Abou-Donia MB, Messer WS Jr, Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc. 2005;53(12):2195–201.
pubmed: 16398909
doi: 10.1111/j.1532-5415.2005.00537.x
Dewey SL, Volkow ND, Logan J, MacGregor RR, Fowler JS, Schlyer DJ, et al. Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET). J Neurosci Res. 1990;27(4):569–75.
pubmed: 2079718
doi: 10.1002/jnr.490270418
Rajan R, Saini A, Verma B, Choudhary N, Gupta A, Vishnu VY, et al. Anticholinergics may carry significant cognitive and gait burden in Parkinson’s disease. Mov Disord Clin Pract. 2020;7(7):803–9.
pubmed: 33043076
pmcid: 7533974
doi: 10.1002/mdc3.13032
Welk B, Richardson K, Panicker JN. The cognitive effect of anticholinergics for patients with overactive bladder. Nat Rev Urol. 2021;18(11):686–700.
pubmed: 34429535
doi: 10.1038/s41585-021-00504-x
Taylor-Rowan M, Edwards S, Noel-Storr AH, McCleery J, Myint PK, Soiza R, et al. Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome. Cochrane Database Syst Rev. 2021;5(5):CD013540.
pubmed: 34097766
Gill SS, Mamdani M, Naglie G, Streiner DL, Bronskill SE, Kopp A, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005;165(7):808–13.
pubmed: 15824303
doi: 10.1001/archinte.165.7.808
Averbeck MA, Altaweel W, Manu-Marin A, Madersbacher H. Management of LUTS in patients with dementia and associated disorders. Neurourol Urodyn. 2017;36(2):245–52.
pubmed: 26588796
doi: 10.1002/nau.22928
Kröger E, Van Marum R, Souverein P, Carmichael PH, Egberts T. Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study. Pharmacoepidemiol Drug Saf. 2015;24(3):276–85.
pubmed: 25652526
doi: 10.1002/pds.3741
Ishii N, Mochizuki H, Sakai K, Ogawa G, Shiomi K, Nakazato M. Polypharmacy associated with cognitive decline in newly diagnosed Parkinson’s disease: a cross-sectional study. Dement Geriatr Cogn Dis Extra. 2019;9(3):338–43.
pubmed: 31608098
pmcid: 6787424
doi: 10.1159/000502351
Sumbul-Sekerci B, Bilgic B, Pasin O, Emre M, Hanagasi HA. Anticholinergic burden, polypharmacy, and cognition in Parkinson's disease patients with mild cognitive impairment: a cross-sectional observational study. Dement Geriatr Cogn Disord. 2022;51(5):386–95.
Bohnen NI, Yarnall AJ, Weil RS, Moro E, Moehle MS, Borghammer P, et al. Cholinergic system changes in Parkinson’s disease: emerging therapeutic approaches. Lancet Neurol. 2022;21(4):381–92.
pubmed: 35131038
pmcid: 8985079
doi: 10.1016/S1474-4422(21)00377-X
Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. Increased blood–brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2003;74(1):70–6.
pubmed: 12486269
pmcid: 1738177
doi: 10.1136/jnnp.74.1.70
Pakulski C, Drobnik L, Millo B. Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monit. 2000;6(2):314–8.
pubmed: 11208329
Callegari E, Malhotra B, Bungay PJ, Webster R, Fenner KS, Kempshall S, et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol. 2011;72(2):235–46.
pubmed: 21392072
pmcid: 3162653
doi: 10.1111/j.1365-2125.2011.03961.x
Geller EJ, Dumond JB, Bowling JM, Khandelwal CM, Wu JM, Busby-Whitehead J, et al. Effect of trospium chloride on cognitive function in women aged 50 and older: a randomized trial. Female Pelvic Med Reconstr Surg. 2017;23(2):118–23.
pubmed: 28067745
doi: 10.1097/SPV.0000000000000374
Collamati A, Martone AM, Poscia A, Brandi V, Celi M, Marzetti E, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging Clin Exp Res. 2016;28(1):25–35.
pubmed: 25930085
doi: 10.1007/s40520-015-0359-7
Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006;50(2):317–26.
pubmed: 16687205
doi: 10.1016/j.eururo.2006.03.057
Bozkurt IH, Sefik E, Celik S, Yesilova A, Koras O, Degirmenci T. On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics. Int Urogynecol J. 2022;33(8):2127–32.
pubmed: 35666289
doi: 10.1007/s00192-022-05250-1